Transforming growth factor beta receptor type 1 and 2 (TGFBR1/2)

Transforming growth factor beta (TGF-beta) receptors type 1 (TGFBR1) and type 2 (TGFBR2) are transmembrane serine/threonine kinases that form a heterotetrameric complex upon binding to TGF-beta ligands [UniProt: P36897, P37173]. This complex is central to the TGF-beta signaling pathway, which regulates a wide array of cellular processes including proliferation, differentiation, and apoptosis [PubMed: 28115566]. In healthy tissues, the pathway acts as a tumor suppressor; however, in advanced cancers, it often promotes metastasis and immune evasion through the induction of epithelial-mesenchymal transition (EMT) [PubMed: 30622534]. Therapeutic strategies targeting these receptors, particularly the kinase activity of TGFBR1 (also known as ALK5), aim to treat various malignancies and fibrotic disorders [PubChem: Galunisertib]. Despite their therapeutic potential, targeting these receptors is challenging due to their pleiotropic effects and potential for systemic toxicities, such as cardiovascular and skin-related adverse events [PubMed: 25605863]. Clinical development continues to focus on identifying optimal dosing schedules and combination therapies to mitigate these risks while maximizing anti-tumor efficacy.

Other names

TGF-beta receptor type ITGF-beta receptor type IIALK5TbetaR-ITbetaR-IIActivin receptor-like kinase 5SKR5AAT5LDS1ALDS2ATGFR-1TGFR-2

Small molecule inhibitors typically target the intracellular kinase domain of TGFBR1 (ALK5) to competitively inhibit ATP binding, thereby preventing the phosphorylation of SMAD2/3 proteins and blocking the downstream signaling cascade initiated by TGF-beta ligand binding [PubMed: 28115566].